Entera Bio LTD. (ENTX) — 10-Q Filings

All 10-Q filings from Entera Bio LTD.. Browse 5 Quarterly Report reports with AI-powered summaries and risk analysis.

10-Q Filings (5)

Entera Bio's Q3 Loss Widens Amid R&D Spend, Revenue Dries Up — Nov 14, 2025 Risk: high
Entera Bio Ltd. (ENTX) reported a net loss of $8.423 million for the nine months ended September 30, 2025, an increase from the $7.183 million net loss in the s
Entera Bio Ltd. Q1 2025 10-Q Filed — May 9, 2025 Risk: low
Entera Bio Ltd. filed its 10-Q for the period ending March 31, 2025. The filing details financial information for the first quarter of 2025, including changes i
Entera Bio Ltd. Files Q3 2024 10-Q — Nov 8, 2024 Risk: medium
Entera Bio Ltd. filed its 10-Q for the period ending September 30, 2024. The company reported financial results and provided updates on its business activities.
Entera Bio Ltd. Files Q2 2024 10-Q Report — Aug 9, 2024 Risk: medium
Entera Bio Ltd. filed its 10-Q for the period ending June 30, 2024. The company reported financial results and provided updates on its business activities. Spec
Entera Bio Ltd. Files 10-Q for Period Ending March 31, 2024 — May 10, 2024 Risk: low
Entera Bio Ltd. (ENTX) filed a Quarterly Report (10-Q) with the SEC on May 10, 2024. Entera Bio Ltd. filed a 10-Q report for the period ending March 31, 2024. T

AAPL · TSLA · MSFT · AMZN · GOOGL · META · NVDA · JPM · BRK-B · V · JNJ · UNH · XOM · WMT · MA · PG · HD · DIS · BAC · NFLX